Preliminary Programme

Thursday May 28, 2015: Continuing Education

Medical Treatment for Ocular Disease

10.30 – 14.45,
Lunch break at 12.00


  • Alison Clode
  • Gigi Davidson
  • Alain Regnier

10.30 – 11.15
Classical treatment of corneal ulcers (A. Clode)
Controversies and dilemmas in treatment of corneal ulcers (A. Regnier)
Pearls and perils of drug therapy for corneal ulcers (G. Davidson)

11.15 – 12.00
Classical treatment of feline herpes (A. Regnier)
Advances in treatment of feline herpes (A. Clode)
Pearls and perils of drug therapy for feline herpes (G. Davidson)

12.00 – 13.00 Lunch break

13.00 – 13.45
Classical treatment of uveitis (A. Clode)
Controversies and dilemmas in treatment of uveitis (A. Regnier)
Pearls and perils of drug therapy for uveitis (G. Davidson)

13.45 – 14.30
Classical treatment of glaucoma (A. Regnier)
Advances in treatment of glaucoma (A. Clode)
Pearls and perils of drug therapy for glaucoma (G. Davidson)

14.30 – 14.45 Q&A, Discussion

14.45 Coffee Break

15.15 ECVO AGM

19.00 Welcome Reception

Friday May 29, 2015: Main Programme

08.30 Opening
08.45 Resident’s Forum Session
10.00 Coffee Break
10.30 Scientific Session
12.00 Lunch
13.00 Poster Session & Industrial Exhibition
14.00 Scientific Session
15.00 Coffee Break - Poster Session & Industrial Exhibition
15.30 Hereditary Eye Diseases Session

HED session program Friday 29 May 2015 16:00-18:00
- Macular corneal dystrophy in the Labrador - Claudia Busse & Roser Tetas
- Canine retinal dysplasia

  • Thoughts on retinal dysplasia - Sheila Crispin 
  • Inconsistent ophthalmoscopic retinal dysplasia signs in Golden Retrievers - Berit Wallin Håkanson
  • Retinal dysplasia in the dog: Are we making a mountain out of a molehill? Gus Aguirre 


End of the afternoon session
19.15 Conference Dinner

Saturday May 30, 2015: Main Programme

08.30 Scientific Session
10.00 Coffee Break - Poster Session & Industrial Exhibition 
10:30 The State of the Art Lecture / The ISVO Magrane Memorial Lecture
“From PGF2α-Isopropyl Ester to Latanoprost: The development of Xalatan, from lab bench to patient bedside”
Prof. Johan Stjernschantz, Department of Neuroscience, Unit of Pharmacology,  Uppsala University, Uppsala, Sweden
12.00 Lunch
13.00 Poster Session & Industrial Exhibition
14.00 Scientific Session
15.00 Coffee Break - Poster Session & Industrial Exhibition  
15.30  Scientific Session
16.30 Closing and awards
17.30 End of the ECVO Annual Meeting

Sunday May 31, 2015: Masterclass
Medical Treatment for Ocular Disease

08.30 What's stopping you? Barriers in drug delivery to the eye - (A. Regnier)
08.50 Deliverance i. drug delivery to the anterior segment - (A. Clode)
09.10 Deliverance ii. drug delivery to the posterior segment - (A. Clode)
09.30 Careful!!! Systemic side-effects of ocular drugs - (A. Regnier)
10.00 First do no harm: Factors influencing safety and efficacy of therapies delivered to the eye - (G. Davidson)
10.30 Break
11.00 Should we be using these drugs? Evidence-based medicine!
  • Ocu-glo - (A. Clode)
  • Tpa - (A. Regnier)
  • Lysine & feline herpes - (A. Clode)
  • Hyperosmotic saline and corneal edema - (A. Regnier)
12.00 How to “vet” a compound when a verified compounding formula is not available - (G. Davidson)

Invited Speakers 2015
Alison Clode, DVM, DACVO

Alison Clode graduated from the Washington State University College of Veterinary Medicine in 2003.  In 2007, she completed her residency in Comparative Ophthalmology at North Carolina State University, where she served as Assistant, and subsequently, Associate Professor of Ophthalmology.  In addition to authoring numerous manuscripts and book chapters, she has served as a member of the ACVO Exam Committee.  In June 2014, Alison left the university and transitioned to private practice in New Hampshire.  Her research and clinical interests are focused upon ocular pharmacology, particularly in relation to corneal disease.

Gigi Davidson, BSPh, DICVP
gigi Gigi Davidson is currently the Director of Clinical Pharmacy Services at the North Carolina State University College of Veterinary Medicine where she has been practicing veterinary pharmacy for more than 30 years.  Ms. Davidson received her BS in Pharmacy from The University of North Carolina at Chapel Hill in 1983 and began work as a clinical veterinary pharmacist at the NC State College of Veterinary Medicine Teaching Hospital in 1983. In 1992 Ms. Davidson was promoted to faculty director of the Veterinary Teaching Hospital Pharmacy.  Ms. Davidson has been precepting pharmacy students since 1989, and teaches a didactic course in veterinary pharmacy at two colleges of pharmacy.  Ms. Davidson is a past president of the Society of Veterinary Hospital Pharmacists and is currently the Government and Regulatory Affairs Liaison for that organization. Ms. Davidson has many publications in peer-reviewed scientific journals and her primary areas of research interest include safety, efficacy and disposition of compounded preparations in animals; immunotherapy for dermatological disease; and evaluation of analgesic therapies in veterinary patients.

Alain Regnier, PhD, Professor of Ophthalmology
a_regnier Alain Regnier was assistant professor and then associate professor of small animal internal medicine (including ophthalmology) at the Veterinary School of Toulouse from 1980 to 1993. During this period he got the French diploma in veterinary ophthalmology and university diplomas in medical statistics and clinical pharmacokinetics (University of Toulouse), and also in ophthalmic microsurgery (University of Paris VII). He also obtained a PhD thesis. He became full professor and head of the small animal clinic at the Veterinary School of Lyon in 1993, before moving back to Toulouse in 1996 where he is currently full professor in ophthalmology. His main field of research is ocular pharmacology and therapeutics.

Johan Stjernschantz, MD, PHD, Professor of Pharmacology
j_stjernschantz Johan Stjernschantz graduated from Helsinki University in 1974 (MD) and presented his thesis (PhD) in 1976 at Helsinki University. In 1977-1978 he worked as a postdoctoral fellow at the Institute of Physiology and Biomedical Physics of Uppsala University in Sweden. 1979-1982 Johan Stjernschantz was a postdoctoral fellow and Assistant Professor of Ophthalmology and Visual Science at Yale University in the US. From 1982 to 1997 Johan Stjernschantz worked in pharmaceutical industry, first in Finland, and from 1986 on in Sweden at Pharmacia Ophthalmics. In Pharmacia he directed the research and development that lead to a new prostaglandin based glaucoma drug (latanoprost; Xalatan®). 1997-2005 Johan Stjernschantz worked at Uppsala University and was appointed Professor of Pharmacology and Drug Development in 1999. Johan Stjernschantz has been Executive editor of Experimental Eye Research, guest editor of Investigative Ophthalmology and Visual Science and been a member of the editorial board of Journal of Ocular Pharmacology and Therapeutics.